Anomalies pigmentaires induites par les traitements anticancéreux. Deuxième partie : les thérapies ciblées

Robert, 2005, Cutaneous side-effects of kinase inhibitors and blocking antibodies, Lancet Oncol, 6, 491, 10.1016/S1470-2045(05)70243-6 Sibaud, 2013, Anomalies pigmentaires induites par les traitements anticancéreux. Première partie : chimiothérapies, Ann Dermatol Venereol, 140, 183, 10.1016/j.annder.2012.12.012 Segaert, 2005, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors, Ann Oncol, 16, 1425, 10.1093/annonc/mdi279 Hu, 2007, Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management, J Am Acad Dermatol, 56, 317, 10.1016/j.jaad.2006.09.005 Agero, 2006, Dermatologic side effects associated with the epidermal growth factor receptor inhibitors, J Am Acad Dermatol, 55, 657, 10.1016/j.jaad.2005.10.010 Lacouture, 2011, Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities, Support Care Cancer, 19, 1079, 10.1007/s00520-011-1197-6 Belloni, 2012, Cutaneous drug eruptions associated with the use of new oncological drugs, Chem Immunol Allergy, 97, 191, 10.1159/000335632 Lacouture, 2006, Mechanisms of cutaneous toxicities to EGFR inhibitors, Nature Rev Cancer, 6, 803, 10.1038/nrc1970 Jatoi, 2010, Does sunscreen prevent growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North central Cancer Treatment Group (NC05C4), Oncologist, 15, 1016, 10.1634/theoncologist.2010-0082 Thatcher, 2009, Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK, Oncologist, 14, 840, 10.1634/theoncologist.2009-0055 Luu, 2011, Higher severity of erlotinib-induced rash is associated with lower skin phototype, Clin Exp Dermatol, 36, 733, 10.1111/j.1365-2230.2011.04117.x Sibaud, 2012, Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology, Ann Chir Plast Esthet, 57, 106, 10.1016/j.anplas.2012.02.002 Sibaud, 2011, Dermatologic side effects induced by new angiogenesis inhibitors, Bull Cancer, 98, 1221, 10.1684/bdc.2011.1457 Grichnik, 1998, The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis, J Invest Dermatol, 111, 233, 10.1046/j.1523-1747.1998.00272.x Tsao, 2003, Imatinib mesylate causes hypopigmentation in the skin, Cancer, 98, 2483, 10.1002/cncr.11812 Arora, 2004, Pigmentary changes in chronic myeloid leukaemia patients treated with imatinib mesylate, Ann Oncol, 15, 358, 10.1093/annonc/mdh068 Amitay-Laish, 2011, Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib, Dermatol Ther, 24, 386, 10.1111/j.1529-8019.2011.01431.x Valeyrie-Allanore, 2010, Cutaneous manifestations of BCR-ABL, c-KIT et PDGFR inhibitors, 41 Brazzelli, 2006, A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients, J Eur Acad Dermatol, 21, 384, 10.1111/j.1468-3083.2006.01981.x Valeyrie, 2003, Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukamias: a prospective study of 54 patients, J Am Acad Dermatol, 48, 201, 10.1067/mjd.2003.44 Alexandrescu, 2008, Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST, Dermatol Online J, 14, 7, 10.5070/D3472203P2 Campbell, 2009, Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome, Arch Dermatol, 145, 1313, 10.1001/archdermatol.2009.263 Mariani, 2010, Reversible hair depigmentation in a patient treated with imatinib, Leukemia Res, 35, e65 Balagula, 2011, Pigmentary changes in a patient treated with imatinib, J Drugs Dermatol, 10, 1062 Cario-Andre, 2006, Imatinib mesylate inhibits melanogenesis in vitro, Br J Dermatol, 155, 493, 10.1111/j.1365-2133.2006.07359.x Etienne, 2002, Imatinib mesylate and grey hair, N Engl J Med, 347, 446, 10.1056/NEJM200208083470614 Han, 2008, Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors, J Am Acad Dermatol, 59, s80, 10.1016/j.jaad.2008.06.029 Sun, 2009, Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor, J Drugs Dermatol, 8, 395 Robert, 2012, Advances in the management of cutaneous toxicities of targeted therapies, Semin Oncol, 39, 227, 10.1053/j.seminoncol.2012.01.009 Li, 2012, Mucosal pigmentation caused by imatinib: report of three cases, Head Neck Pathol, 6, 290, 10.1007/s12105-011-0325-4 Resende, 2012, Imatinib-associated hyperpigmentation of the palate in post-HSCT patient, J Craniomaxillofac Surg, 40, e140, 10.1016/j.jcms.2011.07.010 Mattsson, 2011, Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 111, e12, 10.1016/j.tripleo.2010.11.006 Lewis, 2009, Diffuse pigmentation of the palate, J Okla Dent Assoc, 100, 24 Mcpherson, 2009, Imatinib-associated hyperpigmentation, a side effect that should be recognized, J Eur Acad Dermatol Venereol, 23, 82, 10.1111/j.1468-3083.2008.02706.x Sibaud, 2010, Dermatologic manifestations of angiogenesis inhibitors, 41 Rosenbaum, 2008, Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib, Support Care Cancer, 16, 557, 10.1007/s00520-008-0409-1 Lee, 2009, Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, Br J Dermatol, 161, 1045, 10.1111/j.1365-2133.2009.09290.x Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Robert, 2003, Tyrosine kinase inhibition and grey hair, Lancet, 361, 1056, 10.1016/S0140-6736(03)12805-X Hartmann, 2008, Sunitinib and periodic hair depigmentation due to temporary c-kit inhibition, Arch Dermatol, 144, 1525, 10.1001/archderm.144.11.1525 Al Enazi, 2009, Skin depigmentation induced by sunitinib treatment of renal cell carcinoma, J Am Acad Dermatol, 61, 905, 10.1016/j.jaad.2008.12.030 Keisner, 2011, Pazopanib–the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma, Drugs, 71, 443 Balagula, 2012, The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis, Invest New Drugs, 30, 1773, 10.1007/s10637-011-9652-2 Hurwitz, 2009, Phase I trial of pazopanib in patients with advanced cancer, Clin Cancer Res, 15, 4220, 10.1158/1078-0432.CCR-08-2740 Sternberg, 2010, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol, 28, 1061, 10.1200/JCO.2009.23.9764 Yang, 2010, Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma, Expert Opin Drug Saf, 9, 459, 10.1517/14740331003596349 Yau, 2011, Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics, Clin Cancer Res, 17, 1, 10.1158/1078-0432.CCR-11-0793 Bible, 2010, Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study, Lancet Oncol, 11, 962, 10.1016/S1470-2045(10)70203-5 Sideras, 2010, Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib, J Clin Oncol, 28, e312, 10.1200/JCO.2009.26.4432 Kong, 2008, Sorafenib-induced eruptive melanocytic lesions, Arch Dermatol, 144, 820, 10.1001/archderm.144.6.820 Bennani-Lahlou, 2008, Eruptive naevus associated with sorafenib treatment, Ann Dermatol Venereol, 135, 672, 10.1016/j.annder.2008.04.016 Anforth, 2012, Manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma, Br J Dermatol, 167, 1153, 10.1111/j.1365-2133.2012.11155.x Haenssle, 2012, Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy, Arch Dermatol, 1 Chu, 2012, Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study, J Am Acad Dermatol, 67, 1265, 10.1016/j.jaad.2012.04.008 Zimmer, 2012, Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition, J Clin Oncol, 30, 2375, 10.1200/JCO.2011.41.1660 Dalle, 2011, Vemurafenib in melanoma with BRAF V600E mutation, N Engl Med, 365, 1448, 10.1056/NEJMc1108651 Morabito, 2009, Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions, Oncologist, 14, 378, 10.1634/theoncologist.2008-0261 Wells, 2010, Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer, J Clin Oncol, 28, 767, 10.1200/JCO.2009.23.6604 Kong, 2009, Cutaneous pigmentation after photosensitivity induced by vandetanib therapy, Arch Dermatol, 145, 923, 10.1001/archdermatol.2009.177 Robert, 2010, Vandetanib (Zactima®), 41 Natale, 2011, Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer, J Clin Oncol, 29, 1059, 10.1200/JCO.2010.28.5981 Chang, 2009, Severe photosensitivity reaction to vandetanib, J Clin Oncol, 27, e114, 10.1200/JCO.2009.21.8479 Leboulleux, 2012, Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial, Lancet Oncol, 13, 897, 10.1016/S1470-2045(12)70335-2 Son, 2011, Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel, Ann Dermatol, 23, s314, 10.5021/ad.2011.23.S3.S314 Brooks, 2011, Successful laser treatment of vandetanib-associated cutaneous pigmentation, Arch Dermatol, 147, 364, 10.1001/archdermatol.2011.30 Rappersberger, 1989, Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery, J Invest Dermatol, 93, 201, 10.1111/1523-1747.ep12277571 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621 Weber, 2009, A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma, Clin Cancer Res, 15, 5591, 10.1158/1078-0432.CCR-09-1024 Robert, 2009, What is the role of cytotoxic T lymphocyte-associated antigen 4 blockage in patients with metastatic melanoma?, Oncologist, 14, 848, 10.1634/theoncologist.2009-0028 Trinh, 2012, Ipilimumab in the treatment of melanoma, Expert Opin Biol Ther, 12, 773, 10.1517/14712598.2012.675325 Di Giacomo, 2010, The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications, Semin Oncol, 37, 499, 10.1053/j.seminoncol.2010.09.007 Weber, 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, J Clin Oncol, 30, 2691, 10.1200/JCO.2012.41.6750 Robert, 2010, Manifestations dermatologiques des anticorps anti-CTLA-4, 89 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694